Camrelizumab plus apatinib and SOX as first-line treatment in patients with alpha-fetoprotein-producing gastric or gastroesophageal junction adenocarcinoma: A single-arm, multi-center, phase 2 trial.

被引：0
|
作者：
Wang, Yakun
Wang, Chang
Chen, Xiaofeng
Peng, Zhi
Gu, Yanhong
Wang, Yizhuo
Wang, Xicheng
Li, Jian
Gong, Jifang
Qi, Changsong
Yuan, Jiajia
Lu, Zhihao
Lu, Ming
Shen, Lin
Cao, Yanshuo
Zhang, Xiaotian
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China
[2] First Hosp Jilin Univ, Canc Ctr, Changchun, Jilin, Peoples R China
[3] Nanjing Med Univ, Affiliated Hosp 1, Oncol Dept, Nanjing, Jiangsu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Minist Educ Beijing, Dept Early Drug Dev Ctr, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Early Drug Dev Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
613-135-244-3829; 283-9769-3573-426; 261-492-3532-2370-7650-2700; 3282-270-434-6184; 261-492-3532-2370-5109; 261-492-2769; 261-566-11347; 4; 3; 2; 3599; 239; 2950; 2425; 5; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 351
页数：1
相关论文
共 50 条
  • [41] Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of advanced gastric/gastroesophageal junction cancer: A phase II clinical trial
    Hou, X. F.
    Li, S.
    Wu, C.
    Liu, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S866 - S867
  • [42] Camrelizumab combined with SOX regimen in the first-line treatment of unresectable advanced or recurrent gastric cancer: A single-arm, prospective, open clinical study.
    Han, Zhengxiang
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study
    Han, Sujun
    Ji, Zhigang
    Jiang, Junhui
    Fan, Xinrong
    Ma, Qi
    Hu, Linjun
    Zhang, Wen
    Ping, Hao
    Wang, Jiansong
    Xu, Wanhai
    Shi, Benkang
    Wang, Wei
    Wang, Haifeng
    Wang, Honglei
    Chen, Shouzhen
    Hu, Hailong
    Guo, Jianming
    Zhang, Shen
    Jiang, Shuai
    Zhou, Quan
    Xing, Nianzeng
    CANCER MEDICINE, 2023, 12 (11): : 12106 - 12117
  • [44] Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial
    Xu, Li
    Chen, Jinzhang
    Liu, Chang
    Song, Xiaoling
    Zhang, Yanqiao
    Zhao, Haitao
    Yan, Sheng
    Jia, Weidong
    Wu, Zheng
    Guo, Yabing
    Yang, Jiayin
    Gong, Wei
    Ma, Yue
    Yang, Xiaobo
    Gao, Zhenzhen
    Zhang, Nu
    Zheng, Xin
    Li, Mengyu
    Su, Dan
    Chen, Minshan
    BMC MEDICINE, 2024, 22 (01)
  • [45] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
  • [46] Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.
    Ma, Fei
    Luo, Suxia
    Zhang, Bin
    Ma, Qi
    Ji, Sheqing
    Zhang, Zhandong
    Zhang, Yonglei
    Yang, Wei
    Peng, Liangqun
    Guo, Dandan
    Ren, Jinjun
    Zhang, Yuan
    Su, Yueyue
    Li, Jing
    Liu, Wentao
    Huang, Jinxi
    Yuan, Weiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial
    Zhou, Na
    Zhang, Chuantao
    Liu, Dong
    Liu, Kewei
    Wang, Guanqun
    Zhu, Hua
    Zhang, Jianli
    Jiang, Man
    Liu, Ning
    Zhang, Xiaochun
    ONCOLOGIST, 2021, 26 (03): : E374 - E381
  • [48] Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study
    Wang, Feng
    Liu, Tian-Shu
    Yuan, Xiang-Lin
    Luo, Hui-Yan
    Gu, Kang-Sheng
    Yuan, Ying
    Deng, Yan-Hong
    Xu, Jian-Ming
    Bai, Yu-Xian
    Wang, Ying
    Liao, Wang-Jun
    Zhang, He-Long
    Bi, Feng
    Wang, Bang-Mao
    Zhuang, Zhi-Xiang
    Jiang, Teng-Jia
    Xu, Rui-Hua
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (09): : 3037 - +
  • [49] First-line of camrelizumab plus pyrotinib and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A dose escalation and expansion phase I study.
    Zhu, Liangjun
    Li, Sheng
    Bao, Jun
    Li, Xiaoyou
    Yang, Quanliang
    Xu, Junying
    Chen, Surong
    Feng, Ge
    Gao, Chao
    Feng, Lin
    Lu, Bin
    Miao, Min
    Ni, Xinchu
    Wang, Guofang
    Yang, Lei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 356 - 356
  • [50] Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
    Meng, Xiangrui
    Wu, Tao
    Hong, Yonggui
    Fan, Qingxia
    Ren, Zhonghai
    Guo, Yanzhen
    Yang, Xiuli
    Shi, Pei
    Yang, Jiamei
    Yin, Xianzhe
    Luo, Zhiquan
    Xia, Jin
    Zhou, Yue
    Xu, Mengli
    Liu, Enjie
    Jiang, Guozhong
    Li, Shenglei
    Zhao, Feng
    Ma, Chi
    Ma, Chuanxiang
    Hou, Zhiguo
    Li, Jing
    Wang, Junsheng
    Wang, Feng
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (03): : 245 - 253
12345